Jove
Visualize
Contact Us

Related Experiment Videos

CB2 receptor ligands.

J W Huffman1

  • 1Howard L. Hunter Chemistry Laboratory, Clemson University, South Carolina 29634-0973, USA. huffman@clemson.edu

Mini Reviews in Medicinal Chemistry
|July 20, 2005
PubMed
Summary
This summary is machine-generated.

Researchers explored selective CB(2) receptor ligands, focusing on synthetic compounds like JWH-015 and JWH-133. These molecules show promise for targeting the immune system, distinct from the central nervous system effects of CB(1) receptor agonists.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endocrine problems in women.

Postgraduate medicine·2016
Same author

Diagnosis of secondary amenorrhea.

Pediatric annals·2014
Same author

Adeno carcinoma of the female urethra; a review.

Quarterly bulletin. Northwestern University (Evanston, Ill.). Medical School·2010
Same author

CB2 cannabinoid receptor agonists attenuate TNF-alpha-induced human vascular smooth muscle cell proliferation and migration.

British journal of pharmacology·2007
Same author

Targeting the cannabinoid CB2 receptor: modelling and structural determinants of CB2 selective ligands.

British journal of pharmacology·2007
Same author

Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes.

Current medicinal chemistry·2005
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Pharmacology
  • Medicinal Chemistry
  • Immunology

Background:

  • Cannabinoid receptor 1 (CB(1)) is primarily in the central nervous system, mediating cannabinoid effects.
  • Cannabinoid receptor 2 (CB(2)) is mainly in the immune system, with minimal behavioral impact.
  • Many cannabinoid ligands lack selectivity, binding to both CB(1) and CB(2) receptors.

Purpose of the Study:

  • To review synthetic compounds with significant selectivity for the CB(2) receptor.
  • To discuss structure-activity relationships (SAR) for these selective CB(2) ligands.
  • To highlight recent advancements in identifying novel CB(2)-selective molecules.

Main Methods:

  • Review of literature on synthetic cannabinoid receptor ligands.
  • Analysis of compounds demonstrating selectivity for CB(2) over CB(1).

Related Experiment Videos

  • Examination of structure-activity relationships for identified ligands.

    • Main Results:

    • Several synthetic compounds, including cannabimimetic indoles (e.g., JWH-015) and dibenzopyran derivatives (e.g., JWH-133), exhibit high CB(2) selectivity.
    • JWH-133 demonstrates a two hundred-fold selectivity for CB(2) over CB(1).
    • Recent studies identified CB(2)-selective compounds across diverse structural classes.

    Conclusions:

    • Selective CB(2) receptor ligands have been developed from various chemical scaffolds.
    • Further SAR studies are ongoing to optimize these CB(2)-selective compounds.
    • These selective ligands offer potential for therapeutic applications targeting the immune system.